Halozyme Business Development, ENHANZE® Technology Licensing & Collaboration Agreements

For more information, contact Cindy Atwell, Halozyme Business Development, at bd@halozyme.com

Cindy Atwell is senior director of business development and strategy at Halozyme and joined the company in 2015. Cindy is responsible for leading business development licensing and collaboration discussions as well as strategy initiatives. She works across both pillars of Halozyme’s business – the ENHANZE® drug delivery technology and our novel oncology therapeutics. Cindy played a lead role in the successful signing of the PEGPH20 clinical collaboration with Roche, the signing of new ENHANZE Global Collaboration and Licensing agreements with Bristol-Myers Squibb and Alexion, as well as expanding our ENHANZE agreement with Roche.

Prior to Halozyme, Cindy was in the corporate and business development groups at Impax, AbbVie, and Amylin. At Impax, Cindy worked on a variety of deals focused on marketed or late stage brand products. During her time at AbbVie, Cindy developed the business case for licensing and acquisition opportunities across the rheumatology, gastroenterology, and dermatology therapeutic areas, resulting in multiple significant transactions. Prior to AbbVie, Cindy held various roles at Amylin Pharmaceuticals where she led drug delivery business development efforts, managed early stage therapeutic asset and IP transactions, and supported the launch of BYDUREON as part of the commercial analytics team. Early in her career, Cindy conducted laboratory research focused on discovering and developing infectious disease and cancer treatments at two start-up biotechnology companies.

Cindy holds a BS in biochemistry and molecular biology from the Pennsylvania State University and an MBA from the University of California, San Diego’s Rady School of Management.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.